MedTrace Logo

Changes in the T-wave Alternans in Patients With Heart Failure Treated Wih Sacubitril-Valsartan

NCT04185103 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-12-04

No results posted yet for this study

Summary

The aim of this study is to know if the Sacubitril-Valsartan treatment improves the T-wave alternans in those patients that begin its treatment, which would indirectly show a lower risk of malignant ventricular arrythmias.

Conditions

Interventions

DRUG

Sacubitril-Valsartan

After signing the Informed Consent, in the shortest possible time, the study investigator will carry out an ergometric test for the T-wave alternans (TWA) while still taking the basal medication. The patient will also sign the prototype Informed Consent for carrying out a stress test on a treadmill. It will also be carried out a basal life quality questionnaire, an analytical determination and a colour doppler echocardiography.

Sponsors & Collaborators

  • Agencia Sanitaria Bajo Guadalquivir

    collaborator UNKNOWN

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    lead OTHER

Principal Investigators

  • Antonio José Fernández Romero, Dr · Hospital de Alta Resolución de Utrera

  • Antonio José Fernández Romero, Dr · Hospital de Alta Resolución de Utrera

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2020-11-15
Completion
2020-12-15

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04185103 on ClinicalTrials.gov